cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
The history of Calabria has one of the oldest records of human presence in Italy, beginning around 700,000 BCE when a type of Homo erectus left traces around coastal areas. During the Paleolithic period Stone Age humans created the "Bos Primigenius", a figure of a bull on a cliff created around 10,000 BCE in the Romito Cave in the town of Papasidero. When the Neolithic period came the first villages were founded, around 3,500 BCE. Calabria was at one time the center of the European silk industry.
The European People's Party (EPP), the largest political group inside the Parliament, took the decision to suspend all foreign policy work relating to all matters external to the European Union until the integrity of the procedure could be ensured. The EPP encouraged other parties to follow suit. Dino Giarrusso MEP reported that he and others had been approached by Qatari officials many times: "They were hoping to improve the country's reputation especially in the run-up to the FIFA World Cup". A resolution by Manon Aubry condemning the exploitation of migrant workers in Qatar had stalled in the Parliament for more than one year before passing, due to opposition from the S&D and EPP group. After the scandal broke out, several media organisations noted that Kaili had visited Qatar one month before the scandal, meeting with the Qatari Minister of Labour Ali bin Samikh Al Marri; upon her return to Brussels, she had praised Qatar as a "frontrunner in labour rights" in a speech in front of the European Parliament. Ursula von der Leyen, President of the European Commission, accused Qatar of seeking to buy influence in the European Parliament chamber and that it was of the "utmost concern". Von der Leyen called for a body to be created to uphold the rules on integrity and ethics across all EU institutions. The former president of the European Parliament and current European Commissioner responsible for Foreign Affairs and Security, Josep Borrell, was quoted as saying "the news is very worrisome, very, very worrisome. We are facing some events, some facts that certainly worry me.
=== U.S. relations with Marshall Islands === Section 177 of the 1983 Compact of Free Association between the governments of the United States and the Marshall Islands establishes a process for Marshallese to make a claim against the United States government as a result of damage and injury caused by nuclear testing. That same year, an agreement was signed to implement Section 177, which established a US$150 million trust fund. The fund was intended to generate US$18 million a year, which would be payable to claimants on an agreed-upon schedule. If the US$18 million a year generated by the fund was not enough to cover claims, the principal of the fund could be used. A Marshall Islands Nuclear Claims Tribunal was established to adjudicate claims. In 2000, the tribunal made a compensation award to the people of Enewetak consisting of US$107.8 million for environmental restoration; US$244 million in damages to cover economic losses caused by loss of access and use of the atoll; and US$34 million for hardship and suffering. In addition, as of the end of 2008, another US$96.658 million in individual damage awards were made. Only US$73.526 million of the individual claims award has been paid, however, and no new awards were made between the end of 2008 and May 2010. Due to stock market losses, payments rates that have outstripped fund income, and other issues, the fund was nearly exhausted, as of May 2010, and unable to make any additional awards or payments.
== Human importance == In pisciculture and fishkeeping, the slime coat is important to the health of fish, particularly during transport which can cause damage to it. High ammonia levels in the water can also cause damage to the slime coat. The antimicrobial properties of fish slime have been studied as an alternative to antibiotic drugs to address antibiotic resistance.
Sources: en.wikipedia.org
Bully: David Height: 5'11 Weight: 184 lb Victim(s): Keith and Alex Fighter: Sam Oropeza Height: 6'2 Weight: 183 lb Money earned by Bully: $0 Money earned by victim(s): $10,000 Original airing: This episode aired on September 28, 2012 on MTV 2.
== Preparation == Traditionally, stock is made by simmering various ingredients in water. A newer approach is to use a pressure cooker. The ingredients may include some or all of the following: Bones: Beef and chicken bones are most commonly used; fish is also common. The flavor of the stock comes from the bone marrow, cartilage and other connective tissue. Connective tissue contains collagen, which is converted into gelatin that thickens the liquid. Stock made from bones needs to be simmered for long periods; pressure cooking methods shorten the time necessary to extract the flavor from the bones. Meat: Cooked meat still attached to bones is also used as an ingredient, especially with chicken stock. Meat cuts with a large amount of connective tissue, such as shoulder cuts, are also used. Mirepoix: Mirepoix is a combination of onions, carrots, celery, and sometimes other vegetables added to flavor the stock. Sometimes, the less desirable parts of the vegetables that may not otherwise be eaten (such as carrot skins and celery cores and leaves) are used, as the solids are removed from stock. Herbs and spices: The herbs and spices used depend on availability and local traditions. In classical cuisine, the use of a bouquet garni ('bag of herbs') consisting of parsley, bay leaves, a sprig of thyme, and possibly other herbs, is common. This is often placed in a sachet to make it easier to remove once the stock is cooked.
=== Plants === In green plants, oxygen is a byproduct generated during photosynthesis, and exits through stomata, root cell walls, and other routes. Other materials that are exuded by some plants — resin, saps, latex, are forced from the interior of the plant by hydrostatic pressures inside the plant and by absorptive forces of plant cells. These latter processes do not require added energy, as they act passively. During the pre-abscission phase, deciduous plants excrete by leaf-fall.
=== 2nd Congress (1975) === The CLP held its 2nd Congress in November 1975. The Political Resolution at this Congress stated, "The struggle within the socialist camp is increasingly taking a national form – a form that makes ever more difficult the militant expressions of solidarity of the revolutionary proletariat within the socialist sector.” And, "Our Party … does not choose national sides in this ... struggle that is taking place within the socialist camp. Our Party unconditionally supports revolution and conditionally supports states.” This Political Resolution also discussed globalization, with the CLP viewing it as a the consolidation of an international bourgeoisie. Just before the 3rd Congress, ten members left the CLP. Called the "action faction,” this faction wanted the CLP to become more active in and "build the movement.” The CLP position was that the time was not right for direct action. Instead, the CLP needed to spend more time building class consciousness.. Tension between these two perspectives continued throughout the life of the CLP.
=== Replacement by cysteine in mammals === Most mammal selenoproteins have a small amount (about 10%) of the selenocystine replaced by cystine, increasing to 50% on selenium-deficient diets. This is achieved by SLA/LP accepting thiophosphate instead of selenophosphate, thereby converting the phosphoseryl into a regular cystyl.
Sources: en.wikipedia.org
For instance, in Mexico in 2009, "personal use" quantities were established for a number of drugs – cannabis (5 g), cocaine (0.5 g), heroin (50 mg), methamphetamine (40 mg), LSD (0.015 mg) – possession of which would result in a referral for treatment. A 2023 briefing to the European Parliament noted: "The UN bodies monitoring compliance with the conventions seem to have come to accept these policy choices" of tolerance or administrative rather than criminal penalties.
=== Normal function === Cyclin D1 was originally cloned as a breakpoint rearrangement in parathyroid adenoma and was shown to be required for progression through the G1 phase of the cell cycle to induce cell migration, angiogenesis and to induce the Warburg effect. Cyclin D1 is a protein required for progression through the G1 phase of the cell cycle. During the G1 phase, it is synthesized rapidly and accumulates in the nucleus, and is degraded as the cell enters the S phase. Cyclin D1 is a regulatory subunit of cyclin-dependent kinases CDK4 and CDK6. The protein dimerizes with CDK4/6 to regulate the G1/S phase transition and entry into the S-phase.
==== Children ==== In healthy children, moderate caffeine intake under 400 mg produces effects that are "modest and typically innocuous". As early as six months old, infants can metabolize caffeine at the same rate as that of adults. Higher doses of caffeine (>400 mg) can cause physiological, psychological and behavioral harm, particularly for children with psychiatric or cardiac conditions. There is no evidence that coffee stunts a child's growth. The American Academy of Pediatrics recommends that caffeine consumption, particularly in the case of energy and sports drinks, is not appropriate for children under the age of 18 and should be avoided. This recommendation is based on a clinical report released by American Academy of Pediatrics in 2011 with a review of 45 publications from 1994 to 2011 and includes inputs from various stakeholders (Pediatricians, Committee on nutrition, Canadian Pediatric Society, Centers for Disease Control & Prevention, Food and Drug Administration, Sports Medicine & Fitness committee, National Federations of High School Associations). For children age 12 and under, Health Canada recommends a maximum daily caffeine intake of no more than 2.5 milligrams per kilogram of body weight. Based on average body weights of children, this translates to the following age-based intake limits:
== Role in bone decomposition == Diagenesis alters the proportions of organic collagen and inorganic components (hydroxyapatite, calcium, magnesium) of bone exposed to environmental conditions, especially moisture. This is accomplished by the exchange of natural bone constituents, deposition in voids or defects, adsorption onto the bone surface and leaching from the bone.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.